Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Shi Hyang Lee"'
Autor:
Moon Hee Lee, Seok-Kyu Yoon, Hyungsub Kim, Yong-Soon Cho, Sungpil Han, Shi Hyang Lee, Kyun-Seop Bae, Jina Jung, Sung Hee Hong, Hyeong-Seok Lim
Publikováno v:
Drug Design, Development and Therapy. 17:1107-1114
Moon Hee Lee,1 Seok-Kyu Yoon,1 Hyungsub Kim,2 Yong-Soon Cho,3 Sungpil Han,4 Shi Hyang Lee,1 Kyun-Seop Bae,1 Jina Jung,5 Sung Hee Hong,5 Hyeong-Seok Lim1 1Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37680045ac20f2de506e3cdcda8843dc
https://doi.org/10.2147/dddt.s399264
https://doi.org/10.2147/dddt.s399264
Publikováno v:
Drug design, development and therapy. 16
Hyungsub Kim,1 Shi Hyang Lee,2 Jina Jung,3 Sunghee Hong,3 Hyeong-Seok Lim2 1Department of Emergency Medical Services, College of Health Sciences, Eulji University, Seongnam, Republic of Korea; 2Department of Clinical Pharmacology and Therapeutics, As
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36569768f79f6ef542ec37bfea14a8c2
https://pubmed.ncbi.nlm.nih.gov/35221673
https://pubmed.ncbi.nlm.nih.gov/35221673
Publikováno v:
Journal of Korean Biological Nursing Science. 19:1-10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2f8fac0f280183137585a3d6d9a246d
https://doi.org/10.7586/jkbns.2017.19.1.1
https://doi.org/10.7586/jkbns.2017.19.1.1
LCB01-0371 is a novel oxazolidinone with broad-spectrum activity against Gram-positive pathogens in both in vitro studies and animal infection models. The objectives of this study were to evaluate its safety, tolerability, pharmacokinetics, and pharm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::360a538f3b98c616f0d31ba5c39df9da
https://europepmc.org/articles/PMC6021643/
https://europepmc.org/articles/PMC6021643/
Publikováno v:
Journal of Korean Medical Science
Background In type 2 diabetes mellitus therapy, fixed-dose combination (FDC) can offer not only benefits in glucose control via the combined use of agents, but also increase patient compliance. The aim of this study was to assess the pharmacokinetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1549c6faea9631ff022caa95c13b9b63
https://doi.org/10.3346/jkms.2018.33.e258
https://doi.org/10.3346/jkms.2018.33.e258
Autor:
Yo Han Kim, Hee Youn Choi, Hyeong-Seok Lim, Mi Jo Kim, Jong Hyuk Jung, Hae Sun Jeon, Young Kyoung Lee, Hyun Jeong Kim, Shi Hyang Lee, Kyun-Seop Bae
Publikováno v:
Current Medical Research and Opinion. 31:229-241
Gemigliptin is a selective DPP4 inhibitor used to treat type 2 diabetes. The objective of this study was to evaluate the pharmacokinetics (PKs) of gemigliptin, rosuvastatin, and irbesartan monotherapies and combination therapies.Randomized, open-labe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::891f5d970b29b463317c1ba885beb173
https://doi.org/10.1185/03007995.2014.980886
https://doi.org/10.1185/03007995.2014.980886
Autor:
Kyun-Seop Bae, Keunsu Bang, Hee Youn Choi, Song Han, Mi Jo Kim, Shi Hyang Lee, Hyeong-Seok Lim, Yo Han Kim
Publikováno v:
Drugs in R&D
Purpose Gemigliptin is approved for the treatment of type II diabetes mellitus. Sulfonylureas are commonly used in combination with other antidiabetic drugs to improve glycemic control. The objective of this study was to evaluate the pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecb3d90484260e824c09e5d2e21fa5f3
https://doi.org/10.1007/s40268-014-0054-8
https://doi.org/10.1007/s40268-014-0054-8
Autor:
Yook-Hwan Noh, Hee Youn Choi, Mi Jo Kim, Bogyeong Kim, Kyun-Seop Bae, Hyeong-Seok Lim, Jeong-Ae Kim, Shi Hyang Lee, Yo Han Kim
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 52:381-391
Objectives For patient convenience, a gemigliptin/metformin sustainedrelease fixed-dose combination (FDC) tablet was developed. This study was conducted to investigate the effects of food on the pharmacokinetic (PK) profile of the FDC tablets. Materi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c52aadab93904c051b087ebae97e4c75
https://doi.org/10.5414/cp202038
https://doi.org/10.5414/cp202038
Autor:
Hyeong-Seok Lim, Yo Han Kim, Chin Kim, Hee Youn Choi, Yook-Hwan Noh, Kyun-Seop Bae, Shi Hyang Lee
Publikováno v:
Drug Design, Development and Therapy
Yo Han Kim,1 Hee Youn Choi,1 Yook-Hwan Noh,1 Shi Hyang Lee,1 Hyeong-Seok Lim,1 Chin Kim,2 Kyun-Seop Bae11Department of Clinical Pharmacology and Therapeutics, College of Medicine, University of Ulsan, Asan Medical Center, 2Chong Kun Dang Clinical Res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e472ef389fdf2f081c887f3ad116b47
https://www.dovepress.com/dose-proportionality-and-pharmacokinetics-ofnbspcarvedilol-sustained-r-peer-reviewed-article-DDDT
https://www.dovepress.com/dose-proportionality-and-pharmacokinetics-ofnbspcarvedilol-sustained-r-peer-reviewed-article-DDDT
Autor:
Hyeong-Seok Lim, Hee Youn Choi, Kyun-Seop Bae, Shi Hyang Lee, Yo Han Kim, Yook-Hwan Noh, Mi Jo Kim
Publikováno v:
American journal of cardiovascular drugs : drugs, devices, and other interventions. 14(1)
Valsartan, an angiotensin receptor blocker, is often used with calcium channel blockers (CCBs) such as amlodipine to control hypertension. Recently, the fixed-dose combination (FDC) of amlodipine 10 mg/valsartan 160 mg (Exforge) was approved. Amlodip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e038bd5f7c679b5d689c81165eec9e28
https://pubmed.ncbi.nlm.nih.gov/24174172
https://pubmed.ncbi.nlm.nih.gov/24174172